Strategic Growth Small, specialized biotech focused on canine cancer immunotherapies with recent facility expansion in Lenexa signaling capacity to scale manufacturing and meet rising demand—joint sales opportunities with veterinary clinics, specialty oncology centers, and pet pharma distributors.

Clinical Leadership Leadership and advisory board enhancements including a new Scientific Advisory Board member and established oncology experts present opportunities to position partnerships around clinical trials, co-development conversations, and education for veterinary oncology networks.

Integrated Therapies Pipeline combines autologous cell therapy with immunotherapy approaches (ECI) and oncolytic virotherapy, enabling cross-sell opportunities with clinics offering multimodal cancer care and potential collaborations with diagnostic labs for companion animal oncology profiling.

Regulatory & Market USDA-approved ECI for canine osteosarcoma establishes a credible regulatory foothold; leverage this to pursue broader market access discussions, distribution partnerships, and reimbursement strategy conversations with veterinary distributors and clinics.

Engagement & Growth Active participation in industry events (ACVIM Forum) and a growing commercial team (new CRO earlier, expanding manufacturing) indicate readiness for regional sales initiatives, adopter clinics, and direct-to-clinic education programs to accelerate adoption.